- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01647269
A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome
A Randomised, Controlled, Crossover Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Severe Tourette Syndrome
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This study is aimed at adults who have severe Tourette syndrome and who have found that conventional treatments, such as drugs, do not control their symptoms sufficiently or cannot be tolerated.
The first two clinic visits will involve assessments. Participants will fill in a number of questionnaires and be examined by a psychiatrist and a neurologist. At the second visit, the patient will provide consent for participation and will undergo formal tests to find out if the participant is suitable and willing to undergo the research study and to record the type and severity of their Tourette syndrome symptoms.
The third visit will be an admission to hospital to have the deep brain stimulation (DBS) devices implanted. The admission to hospital should be around five days in duration.
At the first post operative follow-up visit, the patient will be placed into a "stimulator on" group or a "stimulator off" group. To try and make sure that these groups are the same to start with, each patient is put into a group by chance (randomly). This visit will take place around six weeks after surgery. In this trial, the participant will have an equal chance of being in the "on" or the "off" group first. This trial is also a "blinded" trial, neither the patient nor the researchers performing the assessments will know which group the patient is in.
At the next visit, 3 months later, the patient will have a further assessment. If their stimulators have been "on" for the first 3 months, they will be switched off. If they have been "off" they will be switched on.
At the next visit, 3 months later, the patient will be assessed again and then given the opportunity to carry on the trial with the stimulators switched on for long term follow up.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
London, Storbritannien
- UCL Institute of Neurology
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- The participant must be adult with stable Tourette syndrome.
- The participant must have a chronic and severe tic disorder with severe functional impairment, with a Yale Tourette Severity Scale score of at least 35/55 for at least 12 months prior to surgery.
- The participant must have failed conventional medical treatment at therapeutic doses of three classes of medication.
- The participant must not be suitable for behavioural intervention or that this intervention is inappropriate or unsuccessful.
- The participant must have been on stable and optimised treatment of co-morbid conditions for at least 6 months.
- The participant must be actively involved with and compliant with any psychosocial interventions.
- The patient must be compliant with treatment plans.
Exclusion Criteria:
- The tic disorder is attributable to any other condition.
- Any other medical or psychiatric disorders that substantially increase the risk of a failed procedure or that would significantly impede recovery.
- Psychosocial factors which might impede operative and post-operative care and research participation.
- Coagulation problems
- Other disease compromising life expectancy
- Patient likely to benefit from psychological intervention
- Patient unwilling to co-operate with post operative assessment and care
- Pregnancy.
- Participant under 20 years old.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: DBS Off first
|
Bilateral GPi Deep Brain Stimulation
|
Experimentell: DBS On First
|
Bilateral GPi Deep Brain Stimulation
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Change in Yale Global Tic Severity Scale
Tidsram: Three months after stimulation switched ON v three months after stimulation switched OFF
|
The Change in Scores on the Yale Global Tic Severity Scale will be compared between defined periods with stimulation switched ON v stimulation switched OFF.
|
Three months after stimulation switched ON v three months after stimulation switched OFF
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Change in Modified Rush Video Rating scale
Tidsram: Three months after stimulation switched ON v three months after stimulation switched OFF
|
Three months after stimulation switched ON v three months after stimulation switched OFF
|
Change in Yale Brown Obsessive Compulsive Scale
Tidsram: Three months after stimulation switched ON v three months after stimulation switched OFF
|
Three months after stimulation switched ON v three months after stimulation switched OFF
|
Change in Neuropsychiatric Inventory
Tidsram: Three months after stimulation switched ON v three months after stimulation switched OFF
|
Three months after stimulation switched ON v three months after stimulation switched OFF
|
Change in Tourette Quality of life scale
Tidsram: Three months after stimulation switched ON v three months after stimulation switched OFF
|
Three months after stimulation switched ON v three months after stimulation switched OFF
|
Change in MOVES scale
Tidsram: Three months after stimulation switched ON v three months after stimulation switched OFF
|
Three months after stimulation switched ON v three months after stimulation switched OFF
|
Change in Beck Depression Inventory
Tidsram: Three months after stimulation switched ON v three months after stimulation switched OFF
|
Three months after stimulation switched ON v three months after stimulation switched OFF
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Thomas Foltynie, MBBS PhD, UCL Institute of Neurology
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Mentala störningar
- Patologiska processer
- Hjärnsjukdomar
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- Sjukdom
- Genetiska sjukdomar, medfödda
- Basala ganglia sjukdomar
- Rörelsestörningar
- Neurodegenerativa sjukdomar
- Heredodegenerativa störningar, nervsystemet
- Neuropsykiatriska funktionsnedsättningar
- Tic-störningar
- Syndrom
- Tourettes syndrom
Andra studie-ID-nummer
- UCL 11/0226
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Tourettes syndrom
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.AvslutadTidigare behandlat myelodysplastiskt syndrom | Myelodysplastiskt syndrom | Terapierelaterat myelodysplastiskt syndrom | Sekundärt myelodysplastiskt syndrom | Refraktärt högrisk myelodysplastiskt syndromFörenta staterna
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)AvslutadTidigare behandlade myelodysplastiska syndrom | Sekundära myelodysplastiska syndrom | de Novo myelodysplastiska syndromFörenta staterna
-
National Cancer Institute (NCI)AvslutadTidigare behandlade myelodysplastiska syndrom | Sekundära myelodysplastiska syndrom | de Novo myelodysplastiska syndromFörenta staterna
-
TJ Biopharma Co., Ltd.Rekrytering
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RekryteringMyelodysplastiska syndrom (MDS)Förenta staterna, Israel
-
AbbVieCelgene; Genentech, Inc.AvslutadMyelodysplastiska syndrom (MDS)Förenta staterna, Australien, Tyskland
-
AbbVieGenentech, Inc.Aktiv, inte rekryterandeMyelodysplastiska syndrom (MDS)Förenta staterna, Australien, Kanada, Frankrike, Tyskland, Italien, Storbritannien
-
The First Affiliated Hospital with Nanjing Medical...OkändMyelodysplastiska syndrom (MDS)Kina
-
Hospital Universitario GetafeKarolinska Institutet; Medical University of Lodz; Universidad Politecnica... och andra samarbetspartnersOkändSköra äldres syndrom | Svaghet | Frailty syndromPolen, Spanien, Sverige
-
Shaare Zedek Medical CenterOkändPremenstruellt syndrom-PMS
Kliniska prövningar på Bilateral GPi Deep Brain Stimulation
-
Beijing Pins Medical Co., LtdPeking Union Medical College HospitalAvslutad
-
Abbott Medical DevicesAvslutadDepressiv sjukdom, major | Unipolär depressionFörenta staterna, Kanada, Storbritannien
-
University of MinnesotaRekryteringParkinsons sjukdomFörenta staterna
-
University of British ColumbiaAvslutadDjup hjärnstimulering | Krampaktig dysfoni | Laryngeal dystoniKanada
-
George Washington UniversityAvslutadMesial temporallobsepilepsiFörenta staterna
-
University Hospital, GrenobleAvslutadFetma | Hortons huvudvärkFrankrike
-
Stanford UniversityAvslutadParkinsons sjukdomFörenta staterna
-
University of MinnesotaRekrytering
-
North Bristol NHS TrustUniversity of BristolOkändBehandling Resistent depressionStorbritannien
-
Boston Scientific CorporationRekryteringEssentiell tremorTyskland, Korea, Republiken av, Kanada, Belgien, Ungern, Spanien, Portugal, Italien